✦ LIBER ✦

Randomized trial to evaluate the addition of tamoxifen to cyclophosphamide, 5-fluorouracil, prednisone adjuvant therapy in premenopausal women with node-positive breast cancer

✍ Scribed by James N. Ingle; Lloyd K. Everson; H. Sam Wieand; Stephen A. Cullinan; Lester E. Wold; Jeffrey B. Hagen; J. Kirk Martin; James E. Krook; Robert G. Fitzgibbons; John F. Foley; David L. Ahmann; Delano M. Pfeifle; Stephanie J. Green

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 787 KB
Volume: 63
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19890401)63:7<1257::aid-cncr2820630705>3.0.co;2-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adjuvant doxorubicin and cyclophosphamid

Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma : Results of a randomized controlled trial

✍ Soo-Mee Bang; Dae Seog Heo; Ki Hyeong Lee; Jae Ho Byun; Heung Moon Chang; Dong-Y 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

Randomized adjuvant trial to evaluate th

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer: 5-year results from the nishi-nippon group of the adjuvant chemoendocrine therapy for breast cancer organization

✍ Masakazu Toil; Takao Hattori; Masanobu Akagi; Kiyoshi Lnokuchi; Kunzo Orita; Kei 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 714 KB

Background. A randomized adjuvant trial was conducted from October 1982 to January 1985 to evaluate the addition of tamoxifen (TAM) to combination chemotherapy with perioperative mitomycin C (MMC) and ftorafur (FT) for patients with estrogen receptor (ER)-positive tumors and the addition of PSK, a b

Adjuvant six cycles of high-dose adriamy

Adjuvant six cycles of high-dose adriamycin, cyclophosphamide, methotrexate, 5-fluorouracil (ACMF) vs. 12 cycles of low-dose acmf with tamoxifen for premenopausal, node-positive breast cancer patients: Results of a prospective randomized study

✍ Dr. Takashi Fukutomi; Sadako Akashi; Takeshi Nanasawa; Hiroshi Yamamoto 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB

A prospective randomized study was conducted to compare the adjuvant efficacy of six cycles of high-dose ACMF (Adriamycin, ADM; cyclophosphamide, CPA; methotrexate, MTX; 5-fluorouracil, 5-FU) with that of 12 cycles of low-dose ACMF in premenopausal, node-positive breast cancer patients. The six-cycl

Comparison of anastrozole versus tamoxif

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative “Arimidex” compared to Tamoxifen (PROACT) trial

✍ Luigi Cataliotti; Aman U. Buzdar; Shinzaburo Noguchi; Jose Bines; Yuichi Takatsu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract ## BACKGROUND The Pre‐Operative “Arimidex” Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative treatment of postmenopausal women with large, operable (T2/3, N0‐2, M0), or potentially operable (T4b, N0‐2, M0) br

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views